EUVIMEDEUVIMED entdecken
Crossref

Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma

Michihisa Moriguchi iD, Keiichiro Okuda, Go Horiguchi, Seita Kataoka, Yuya Seko iD, Kanji Yamaguchi iD, Takeshi Nishimura, Hideki Fujii, Yasuhide Mitsumoto, Masami Miyagawa, Toshihiko Kirishima, Shinya Okishio und 14 weitere

Liver International · 2024

DOI: 10.1111/liv.15918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Michihisa Moriguchi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti‐platelet agents or anticoagulants.

Methods

Patients were divided into those using (IM out) and those not using (IM in) anti‐platelet agents or anticoagulants, who violated the exclusion criteria of the IMbrave150 trial, and were retrospectively examined.

Results

The study included 185 patients (IM in: 157; IM out: 28). For first‐line treatment, progression‐free survival was 184 days for IM in and 266 days for IM out ( p = .136). Overall survival was 603 days for IM in and not reached for IM out ( p = .265), with no significant between‐group difference. Similarly, there were no significant between‐group differences in progression‐free survival or overall survival for later‐line treatment. Haemorrhagic adverse events of ≥grade 3 were observed in 11 IM in patients and 3 IM out patients. No significant factors associated with haemorrhagic adverse events of ≥grade 3 were identified in the multivariate analysis including IM out classification, whose p value was .547. Regarding thrombotic/embolic adverse events in the IM out group, one case of exacerbation of portal vein thrombosis was observed. No deaths were directly attributable to bleeding events or exacerbations of thrombosis.

Conclusion

Atezolizumab + bevacizumab therapy shows similar safety and efficacy in patients receiving and those not receiving anti‐platelet agents or anticoagulants; therefore, it can be considered for patients with hepatocellular carcinoma receiving anti‐platelet agents or anticoagulants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabAntibodies, Monoclonal, HumanizedPlatelet Aggregation InhibitorsAnticoagulantsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsProgression-Free SurvivalHemorrhageAdult

Stichwörter der Autor:innen

anticoagulant therapyanti‐platelet therapyatezolizumab + bevacizumabhepatocellular carcinoma

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabPlatelet Aggregation InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
  • Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
  • Department of Gastroenterology, Kyoto City Hospital, Kyoto, Japan.
  • Department of Gastroenterology, Fukuchiyama City Hospital, Kyoto, Japan.

ORCID-Profile: Michihisa Moriguchi, Yuya Seko, Kanji Yamaguchi

Zitieren

APA

Moriguchi, M., Okuda, K., Horiguchi, G., Kataoka, S., Seko, Y., Yamaguchi, K., Nishimura, T., Fujii, H., Mitsumoto, Y., Miyagawa, M., Kirishima, T., Okishio, S., Hara, T., Ishikawa, H., Nagao, Y., Jo, M., Ishii, M., Tanaka, S., Yamauchi, N., …, & Itoh, Y. (2024). Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma. Liver International. https://doi.org/10.1111/liv.15918

Vancouver

Moriguchi M, Okuda K, Horiguchi G, Kataoka S, Seko Y, Yamaguchi K, et al. Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma. Liver International. 2024. doi:10.1111/liv.15918

BibTeX
@article{Moriguchi2024,
  author = {Moriguchi, Michihisa and Okuda, Keiichiro and Horiguchi, Go and Kataoka, Seita and Seko, Yuya and Yamaguchi, Kanji and Nishimura, Takeshi and Fujii, Hideki and Mitsumoto, Yasuhide and Miyagawa, Masami and Kirishima, Toshihiko and Okishio, Shinya and Hara, Tasuku and Ishikawa, Hiroki and Nagao, Yasuyuki and Jo, Masayasu and Ishii, Michiaki and Tanaka, Saiyu and Yamauchi, Norihito and Mitsuyoshi, Hironori and Nakajima, Tomoki and Taketani, Hiroyoshi and Yano, Kota and Arai, Masahiro and Umemura, Atsushi and Itoh, Yoshito},
  title = {Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15918}
}
Kostenlos starten →